89bio, INC Schedule 13D activist filings

RA Capital Management has fully divested its holdings in 89bio, Inc. following the company's acquisition by Roche Holdings, Inc. for $14.50 cash plus a contingent value right.

Adage Capital Management and its principals have fully divested their 13.1 million shares in 89bio, Inc. through a tender offer at $14.50 cash per share plus a contingent value right.

Adage Capital Management, L.P. and its principals have disclosed a 6.13% beneficial ownership stake in 89bio, Inc., acquired for investment purposes in anticipation of the company's merger with Roche Holdings, Inc.

RA Capital Management and its affiliates have reaffirmed their aggregate 13.7% beneficial ownership in 89bio, Inc., reflecting an updated total outstanding share count for the biopharmaceutical company.

RA Capital Management, L.P. and its affiliates have increased their beneficial ownership in 89bio, Inc. to 15.1% of outstanding common stock after purchasing shares in the company's recent public offering.